Mesoblast Corporate Update: Analyst Call
September 09 2019 - 7:40PM
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular
medicines for inflammatory diseases, will provide a corporate
update during an analyst call today. The webcast will begin at
8.30pm EDT Monday September 9, 2019; 10.30am AEST Tuesday September
10, 2019. The webcast can be accessed via
https://webcasting.boardroom.media/broadcast/5d71f3b98ab2617d254fa91c To
access the call only, dial 1 855 881 1339 (U.S.), 1 800 558 698
(toll-free Australia) or +61 2 9007 3187 (outside of the U.S. and
Australia). The conference identification code is 10002044.
The archived webcast will be available on the Investor page of
the Company’s website: www.mesoblast.comAbout
Mesoblast Mesoblast Limited (Nasdaq: MESO; ASX:MSB) is a
world leader in developing allogeneic (off-the-shelf) cellular
medicines. The Company has leveraged its proprietary technology
platform to establish a broad portfolio of late-stage product
candidates with three product candidates in Phase 3 trials – acute
graft versus host disease, chronic heart failure and chronic low
back pain due to degenerative disc disease. Through a proprietary
process, Mesoblast selects rare mesenchymal lineage precursor and
stem cells from the bone marrow of healthy adults and creates
master cell banks, which can be industrially expanded to produce
thousands of doses from each donor without the need for tissue
matching. Mesoblast has facilities in Melbourne, New York,
Singapore and Texas and is listed on the Australian Securities
Exchange (MSB) and on the Nasdaq (MESO).
www.mesoblast.com
For further information, please contact: |
|
|
Julie Meldrum |
Schond Greenway |
Corporate Communications |
Investor Relations |
T: +61 3 9639 6036 |
T: +1 212 880 2060 |
E: julie.meldrum@mesoblast.com |
E: schond.greenway@mesoblast.com |
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Jul 2023 to Jul 2024